HPV E7 Monoclonal Antibody for Cervical Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting HPV E7 proteins in cervical cancer are hindered by low expression levels, immunosuppression activity, and cross-reactivity issues, leading to inadequate specificity and sensitivity, particularly for early-stage cervical cancer diagnosis.
Innovation Solution
Development of a monoclonal antibody with high affinity for HPV16 E7 and HPV18 E7 proteins, specifically designed to detect and differentiate between these proteins, utilizing a recombinant protein immunization approach and hybridoma technology to produce antibodies with distinct binding activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods (Pap smear, HPV DNA detection) are used, then detection coverage is achieved, but sensitivity and specificity are insufficient for early-stage cervical cancer diagnosis
Solution Approach 1:
The patent changes the detection target from viral DNA presence to oncoprotein expression levels. By detecting E6/E7 oncoproteins instead of HPV DNA, the method achieves higher sensitivity (95.2%) and specificity (98.7%) for early-stage cervical cancer, resolving the contradiction between detection coverage and diagnostic accuracy
Solution Approach 2:
The patent introduces E6/E7 oncoproteins as intermediary markers between HPV infection and cervical cancer development. These proteins serve as a mediator that reflects both viral presence and carcinogenic activity, enabling more reliable early detection while reducing false positives and negatives
2Measurement precision
If HPV DNA detection is used to identify high-risk HPV, then sensitivity improves, but ability to distinguish continuous infection from instantaneous infection is lost
Solution Approach 1:
The patent shifts from detecting viral genetic material (DNA) to detecting functional oncoproteins (E6/E7). This parameter change preserves sensitivity while recovering infection duration information, as oncoprotein persistence indicates continuous infection rather than transient exposure
3Ease of operation
If morphological test by Pap smear is used, then simplicity is maintained, but dependence on expert experience and repeatability are compromised
Solution Approach 1:
The patent replaces subjective morphological evaluation with objective oncoprotein detection. By measuring E6/E7 protein levels through immunodetection rather than visual assessment of cell morphology, the method maintains operational simplicity while achieving superior repeatability and reducing expert dependency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monoclonal antibody achieves high specificity and sensitivity in detecting HPV E7 proteins, enabling early-stage cervical cancer diagnosis and identifying HPV types, with a binding affinity of 0.64 nM for HPV16 E7 and 1.52 nM for cervical cancer cell lines, facilitating accurate identification of HPV-positive cells even at low concentrations.
Implementation Method 1
The monoclonal antibody achieves high specificity and sensitivity in detecting HPV E7 proteins, enabling early-stage cervical cancer diagnosis and identifying HPV types, with a binding affinity of 0.64 nM for HPV16 E7
Data Source
Figure 1~2B
Figure 3A~3B
Figure 4~5
AI summary
The present invention provides an anti-HPV E7 protein monoclonal antibody and the use thereof. The antibody can detect the HPV16 E7 protein with high specificity and recognize the HPV18 E7 protein, thereby it can distinguish between the cancerous cervical epithelial cells and the cervical abnormal or non-cancerous cervical epithelial cells.